newsfilter
← Latest News
Business Wire·

CytRx Notes Orphazyme's Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") announced it has